Report Feature
The future of the global next generation cancer diagnostic market looks promising with opportunities in biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis. The global next generation cancer diagnostic market is expected to grow with a CAGR of 21%-23% from 2020 to 2025. The major drivers for this market are increasing prevalence of oncology diseases and growing demand for efficient cancer screening tests.
Emerging trends, which have a direct impact on the dynamics of the industry, include growing adoption of point-of-care testing and advancement in next generation sequencing technologies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global next generation cancer diagnostic market report, please download the report brochure.
In this market, lung is the largest cancer site of next generation cancer diagnostic, whereas biomarker development is the largest application. Growth in various segments of the next generation cancer diagnostic market are given below:
The study includes trends and forecast for the global next generation cancer diagnostic market by cancer site, test purpose, test platform, application, and region as follows:
By Cancer Site [Value ($ Million) shipment analysis for 2014 – 2025]:
- Bladder
- Brain
- Breast
- Colorectal
- Cancer Of Unknown Primary
- Gastric
- Gynecologic
- Hematologic
- Kidney
- Liver
- Lung
- Pan-Cancer
- Pancreatic
- Prostate
- Melanoma
- Thyroid
By Test Purpose [Value ($ Million) shipment analysis for 2014 – 2025]:
- Screening/Early Detection
- Diagnosis
- Monitoring
- Therapy Guidance
By Test Platform [Value ($ Million) shipment analysis for 2014 – 2025]:
- Arrays/Microfluidics
- Cell/EV Capture
- Multiplex Conventional
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
- Biomarker Development
- CTC Analysis
- Proteomic Analysis
- Epigenetic Analysis
- Genetic Analysis
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- France
-
Asia Pacific
- China
- India
- Japan
-
The Rest of the World
- Brazil
Some of the next generation cancer diagnostics companies profiled in this report include Cepheid, Philips, Roche, Qiagen, Novartis, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, and GE Healthcare.
Lucintel forecasts that lung cancer will remain the largest cancer site segment over the forecast period due to increasing pollution and adoption of smoking that leads to increasing cases of lung cancer.
Within this market, biomarker development will remain the largest segment by application over the forecast period due to increasing discovery and development of drugs.
North America will remain the largest region over the forecast period due to increasing investment in research and development, favorable government initiatives (such as movement for colon cancer detection), and increasing demand for personalized medicines in the region.
|
Features of the Global Next Generation Cancer Diagnostic Market |
|
|
This report answers following key questions |
|
Q.1 What are some of the most promising potential, high-growth opportunities for the global next generation cancer diagnostic market by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), test purpose (screening/early detection, diagnosis, monitoring, and therapy guidance), test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, polymerase chain reaction (PCR), and next generation sequencing (NGS)), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis), and region (North America, Europe, Asia Pacific, and Rest of the World)? Q.2 Which segments will grow at a faster pace and why? Q.3 Which region will grow at a faster pace and why? Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global next generation cancer diagnostics market? Q.5 What are the business risks and threats to the global next generation cancer diagnostic market? Q.6 What are the emerging trends in the next generation cancer diagnostic market and the reasons behind them? Q.7 What are some changing demands of customers in the next generation cancer diagnostic market? Q.8 What are the new developments in the next generation cancer diagnostic market? Which companies are leading these developments? Q.9 Who are the major players in the next generation cancer diagnostic market? What strategic initiatives are being implemented by key players for business growth? Q.10 What are some of the competitive products and processes in the next generation cancer diagnostic market, and how big of a threat do they pose for loss of market share via material or product substitution? Q.11 What M&A activities did take place in the last five years in the global next generation cancer diagnostic market? |
Report Scope
| Key Features | Description |
| Base Year for Estimation | 2019 |
|
Trend Period (Actual Estimates) |
2014-2019 |
| Forecast Period | 2020-2025 |
| Pages | More than 150 |
| Market Representation / Units | Revenue in US $ Million |
| Report Coverage | Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Ventures, and Company Profiling |
| Market Segments | Cancer Site (Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid), Test Purpose (Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance), Test Platform (Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, and PCR and NGS), and Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis) |
Regional Scope |
North America (USA, Mexico, and Canada), Europe (UK, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil) |
| Customization | 10% Customization without Any Additional Cost |
Table of Contents
1. Executive Summary
7.2 Emerging Trends in the Global Next Generation Cancer Diagnostic Market
4.1 Global Next Generation Cancer Diagnostic Market by Region
4.2.1 Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.2.2 Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.2.3 Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.2.4 Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.2.5 The United States Next Generation Cancer Diagnostic Market
4.2.6 The Canadian Next Generation Cancer Diagnostic Market
4.2.7 The Mexican Next Generation Cancer Diagnostic Market
4.3.1 Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.3.2 Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.3.3 Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.3.4 Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.3.5 The Next Generation Cancer Diagnostic Market of the United Kingdom
4.3.6 The German Next Generation Cancer Diagnostic Market
4.3.7 The French Next Generation Cancer Diagnostic Market
4.4.1 Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.4.2 Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.4.3 Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.4.4 Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.4.5 The Chinese Next Generation Cancer Diagnostic Market
4.4.6 The Indian Next Generation Cancer Diagnostic Market
4.4.7 The Japanese Next Generation Cancer Diagnostic Market
4.5.1 Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.5.2 Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.5.3 Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.5.4 Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.5.5 Brazilian Next Generation Cancer Diagnostic Market
7.1.1 Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Cancer Site
7.1.2 Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Test Purpose
7.1.3 Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Test Platform
7.1.4 Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Application
7.1.5 Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
